These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15490029)

  • 1. Exercise-provoked bidirectional ventricular tachycardia in a young woman.
    Lin YH; Lai LP; Lin TK; Lin JL
    J Formos Med Assoc; 2004 Oct; 103(10):780-3. PubMed ID: 15490029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
    Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
    Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
    Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH
    Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
    Heiner JD; Bullard-Berent JH; Inbar S
    Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Rosso R; Kalman JM; Rogowski O; Diamant S; Birger A; Biner S; Belhassen B; Viskin S
    Heart Rhythm; 2007 Sep; 4(9):1149-54. PubMed ID: 17765612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise-induced polymorphic ventricular tachycardia in adults without structural heart disease.
    Tan JH; Scheinman MM
    Am J Cardiol; 2008 Apr; 101(8):1142-6. PubMed ID: 18394448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.
    Sumitomo N; Harada K; Nagashima M; Yasuda T; Nakamura Y; Aragaki Y; Saito A; Kurosaki K; Jouo K; Koujiro M; Konishi S; Matsuoka S; Oono T; Hayakawa S; Miura M; Ushinohama H; Shibata T; Niimura I
    Heart; 2003 Jan; 89(1):66-70. PubMed ID: 12482795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise-induced bidirectional ventricular tachycardia with alternating right and left bundle branch block-type patterns--a case report.
    Khan IA
    Angiology; 2002; 53(5):593-8. PubMed ID: 12365869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mutation in the RYR2 gene leading to catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation: dose-dependent arrhythmia-event suppression by β-blocker therapy.
    Kazemian P; Gollob MH; Pantano A; Oudit GY
    Can J Cardiol; 2011; 27(6):870.e7-10. PubMed ID: 21652165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia.
    Peltenburg PJ; Kallas D; Bos JM; Lieve KVV; Franciosi S; Roston TM; Denjoy I; Sorensen KB; Ohno S; Roses-Noguer F; Aiba T; Maltret A; LaPage MJ; Atallah J; Giudicessi JR; Clur SB; Blom NA; Tanck M; Extramiana F; Kato K; Barc J; Borggrefe M; Behr ER; Sarquella-Brugada G; Tfelt-Hansen J; Zorio E; Swan H; Kammeraad JAE; Krahn AD; Davis A; Sacher F; Schwartz PJ; Roberts JD; Skinner JR; van den Berg MP; Kannankeril PJ; Drago F; Robyns T; Haugaa K; Tavacova T; Semsarian C; Till J; Probst V; Brugada R; Shimizu W; Horie M; Leenhardt A; Ackerman MJ; Sanatani S; van der Werf C; Wilde AAM
    Circulation; 2022 Feb; 145(5):333-344. PubMed ID: 34874747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
    Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
    Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catecholaminergic polymorphic ventricular tachycardia with associated sinus node dysfunction.
    Joshi P; Saxena A; Kaul U; Mansoor AH
    Indian Heart J; 2010; 62(1):84-6. PubMed ID: 21180045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Catecholaminergic polymorphic ventricular tachycardia].
    Leren IS; Haugaa KH; Edvardsen T; Anfinsen OG; Kongsgård E; Berge KE; Leren TP; Amlie JP
    Tidsskr Nor Laegeforen; 2010 Jan; 130(2):139-42. PubMed ID: 20125202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients.
    Leenhardt A; Lucet V; Denjoy I; Grau F; Ngoc DD; Coumel P
    Circulation; 1995 Mar; 91(5):1512-9. PubMed ID: 7867192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Vaksmann G; Klug D
    Pacing Clin Electrophysiol; 2018 Oct; 41(10):1378-1380. PubMed ID: 29989676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers.
    Mazzanti A; Kukavica D; Trancuccio A; Memmi M; Bloise R; Gambelli P; Marino M; Ortíz-Genga M; Morini M; Monteforte N; Giordano U; Keegan R; Tomasi L; Anastasakis A; Davis AM; Shimizu W; Blom NA; Santiago DJ; Napolitano C; Monserrat L; Priori SG
    JAMA Cardiol; 2022 May; 7(5):504-512. PubMed ID: 35353122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Claudio B; Alice M; Daniel S
    Mini Rev Med Chem; 2018; 18(6):476-482. PubMed ID: 28685702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.